YOKNEAM, Israel, July 2, 2012 /PRNewswire/ -- Syneron Medical Ltd.
(NASDAQ: ELOS), www.syneron.com, the global leader in medical
aesthetic products and technology, announced today that it has
received United States Food and Drug Administration (FDA) clearance
for elos Plus™, a next generation multi-platform system featuring
the Company's proprietary elos technology. The FDA clearance for
elos Plus™ follows on the recent international launch in
Europe and Asia.
(Logo: http://photos.prnewswire.com/prnh/20120528/535447 )
"The vision for the elos Plus™ was to bring to market the most
comprehensive multi-platform system that out-delivers the
competition in performance, reliability and scalability," said
Louis P. Scafuri, Chief Executive
Officer at Syneron. "Our new system was designed to grow with any
size practice and caters to a diverse patient population. It
has the capacity to deliver a full range of aesthetic treatments
and is equipped with the most advanced features for optimum speed,
safety and performance. We believe elos Plus™ will appeal to a
broad range of customers and allow them to customize their
investment to meet the demand of their individual practice."
The new elos Plus™ leverages the Company's proprietary elos®
technology of optical energy and bi-polar radiofrequency to provide
safe and efficacious treatments. This state-of-the-art system is
customizable or upgradable utilizing a full range of up to eight
in-demand aesthetic applicators, which also includes the Company's
globally successful Sublative™ and Sublime™ applications. The
intuitive fifteen-inch touch screen offers unparalleled ease-of-use
through its simple but powerful guided treatment modes for all
applications. The system is also equipped with the most popular
features from recent Syneron models such as the proprietary Active
Dermal Monitoring™, Intelligent Feedback System™ (IFS) and
Sublative iD™, making elos Plus™ the new workhorse for any
aesthetic practice.
"Having owned several generations of elos™ models, the elos
Plus™ is equipped with all the best assets I've come to count on
and more," said Vince Afsahi, M.D.,
board certified Dermatologist and Medical Director at South Coast
Dermatology Institutes in Newport
Beach and Tustin,
California. "The intuitive and interactive user interface of
the elos Plus™ improves user experience, while the additional
safety measures such as the IFS, which is now available on all
applications, ensures maximum treatment delivery without
compromising patient safety or comfort."
For more information about elos Plus™ or any of Syneron's broad
product offering, visit www.syneron.com.
About Syneron Medical Ltd.
Syneron Medical Ltd. – a company devoted to real technology,
real science and real results – is the leading global aesthetic
device company with a comprehensive product portfolio and a global
distribution footprint. The Company's technology enables
physicians to provide advanced solutions for a broad range of
medical-aesthetic applications including body contouring, hair
removal, wrinkle reduction, rejuvenation of the skin's appearance
through the treatment of superficial benign vascular and pigmented
lesions, and the treatment of acne, leg veins and cellulite.
The Company sells its products under two distinct brands,
Syneron and Candela. The Company's aspiration and commitment
to innovation expands Syneron's offering beyond medical device into
the largest in-demand applications in beauty - skin lightening.
Founded in 2000, the corporate, R&D, and manufacturing
headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and
manufacturing operations in the US. The company markets and
services and supports its products in 86 countries. It has offices
in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan,
and Hong Kong and distributors
worldwide. Additional information can be found at
www.syneron.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future
expectations, beliefs, goals, plans or prospects constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Further, any statements
that are not statements of historical fact (including statements
containing "believes," "anticipates," "plans," "expects," "may,"
"will," "would," "intends," "estimates" and similar expressions)
should also be considered to be forward-looking statements. There
are a number of important factors that could cause actual results
or events to differ materially from those indicated by such
forward-looking statements, including the risk that the businesses
of Syneron and Candela may not be integrated successfully; the risk
that the merger transaction with Candela may involve unexpected
costs or unexpected liabilities; the risk that synergies from the
merger transaction may not be fully realized or may take longer to
realize than expected; the risk that disruptions from the merger
transaction make it more difficult to maintain relationships with
customers, employees, or suppliers; as well as the risks set forth
in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F,
and the other factors described in the filings that Syneron Medical
Ltd. makes with the SEC from time to time. If one or more of these
factors materialize, or if any underlying assumptions prove
incorrect, Syneron Medical Ltd.'s actual results, performance or
achievements may vary materially from any future results,
performance or achievements expressed or implied by these
forward-looking statements.
In addition, the statements in this document reflect the
expectations and beliefs of Syneron Medical Ltd. as of the date of
this document. Syneron Medical Ltd. anticipates that subsequent
events and developments will cause its expectations and beliefs to
change. However, while Syneron Medical Ltd. may elect to update
these forward-looking statements publicly in the future, it
specifically disclaims any obligation to do so. The forward-looking
statements of Syneron Medical Ltd. do not reflect the potential
impact of any future dispositions or strategic transactions that
may be undertaken. These forward-looking statements should not be
relied upon as representing Syneron Medical Ltd.'s views as of any
date after the date of this document.
SOURCE Syneron Medical Ltd.